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Introduction
Sorafenib is an orally active multikinase inhibitor blocking both 
tumor cell proliferation and angiogenesis. It is currently approved 
for the treatment of  advanced renal cell cancer and hepatocellular 
carcinoma.
Skin toxicity, such as hand-foot skin reaction (HFSR), is one of  
the frequent adverse effects of  sorafenib; it is dose dependent and 
disappears with discontinuation of  sorafenib. On the other hand, 
erythema multiforme (EM) and Stevens-Johnson syndrome (SJS) 
are the very rare side effects of  sorafenib. We report a case of  SJS 
caused by sorafenib for hepatocellular carcinoma.
Case Report
34-year old woman was follow-up in gastroenterology department 
for hepatocellular carcinoma complicating hepatitis B traited by 
sebivo, she have been put under Sorafenib (400mg/day), 10 days 
after the start of  Sorafenib the patient presented erythematous 
itchy rash at the two lower limbs and upper limb  with extension 
to trunk and face.
Dermatological examination had found: erythematous target le-
sion in the upper limbs and back (Figure 1), urticarial plaques on 
the trunk, purpuric  lesions on the lower extremities and blisters 
stretched at the back side of  2 feet and achieving of  the buccal 
and genital mucosa (Figure 2).
Admission laboratory tests revealed several abnormal finding: 
hypereosinophilia in 2100 element/mm3 and hepatic cytolysis 
(SGOT=92 UI/L→2xN, SGPT=188 UI/L→4xN).
Skin biopsy revealed parakeratosis, focal spongiosis, and perivas-
cular inflammation.  According to the clinical, biological and his-
topathologic findings, the patient was diagnosed as having SJS. 
She discontinued sorafenib therapy and she was treated sympto-
matically with good clinical and biological outcome.
Discussion
We report the second case of  SJS induced by sorafenib for hepa-
tocellular carcinoma; the first one was reported by Ikeda et al in 
patient with metastatic renal cell carcinoma [1].
Sorafenib belongs to the family of  targeted therapies that are 
new anti-cancer drugs entering clinical practice that target spe-
cific mechanisms responsible for cell growth, spread and survival. 
One new drug, sorafenib, has been introduced in the treatment 
of  hepatocellular carcinoma, to radically change the prognosis of  
these patients [2].
Sorafenib is a potent inhibitor of  Raf-1, a key enzyme in the Ras/
Raf/MEK/ERK signaling pathway  leading  to  cell prolifera-
tion.  It interferes with both the angiogenesis and the endothelial 
growth factor receptor (EGFR) pathway.  Early  trials  have  dem-
onstrated  the  antitumor  potential  of   sorafenib  in  patients 
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Abstract
Background: Sorafenib is a new therapeutic agent being used in hepatocellular carcinoma, renal cell carcinoma and malignant 
melanoma. The most frequently seen cutaneous side effects due to sorafenib are erythema, exfoliative dermatitis, acne vulgaris 
and hand-foot skin reaction. Erythema multiforme, stevens-johnson syndrome are rare side effects of  sorafenib.
Observation: We present a 34-years-old woman with stevens-Johnson syndrome induced by sorafenib for hepatocellular 
carcinoma. 
Conclusion: Patients treated with sorafenib for HCC should be monitored closely with a multidisciplinary approach, and if  
SJS is diagnosed, these patients cannot be given sorafenib again.
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with  hepatocellular  carcinoma, melanoma,  non–small  cell  lung 
cancer  (NSCLC),  cancers  of   the  pancreas  and  colon,  and 
other  solid tumors [2, 3].
Extra-dermatological side effects related to sorafenib are fatigue, 
hypertension, Arterial thromboembolic events, Hemorrhage 
complications, including epistaxis, hemoptysis, hematemesis, 
gastrointestinal, vaginal and cerebral hemorrhage, have been de-
scribed as severe and mortality-related adverse effects in patients 
treated with sorafenib [4].
 
Skin toxicity is the most common adverse events induced by 
sorafenib. W.J.Lee et al reported that hand-and-foot skin reaction 
(HFSR  ) was the most common cutaneous toxicity (48%) char-
acterized  by  well-demarcated,  tender, erythematous  papules 
and  plaques  with  grayish  blisters  or hyperkeratotic, callus-like 
formations on palmoplantar surfaces  and  distal  phalanges. Oth-
ers cutaneous toxicities included alopecia (26%), stomatitis (26%) 
and erythematous eruption on the trunk (20%) [5].
Stevens-Johnson syndrome was first described in 1922 as an ex-
traordinary, generalized epidermal eruption. It is accompanied by 
fever, inflammation of  the buccal mucosa, and severe purulent 
conjunctivitis. Incidence of  this disorder is unknown, but it is 
thought to be very low. The etiology of  this disorder is multiple, 
including drugs such as (Nevirapine, Carbamazepine,  Pheny-
toin,  Phenobarbital, Allopurinol and Quinolones …), infectious 
agents, and idiopathic causes [6, 7].
 
Clinically, SJS is characterized by confluent purpuric macules or 
atypical flat targetoid lesions, with blisters and erosions covering 
<10% of  body surface area [7].
The mortality rate mainly depends on the age and health of  the 
patient, and rates can range from 30 to 100 percent. Individuals 
at opposite ends of  the age spectrum, the very young and the 
old, are usually fatal cases. Death is commonly due to infectious 
complications [6].
Ikeda et al. reported the first Sorafenib-induced SJS. They de-
scribed a 67-year-old man with lymph node and bone metastases 
from clear-cell received sorafenib(800mg/day). As in our case, 
ten days after sorafenib initiation, the patient presented clinical 
sign of  SJS. The patient discontinued sorafenib treatement and 
was treated with prednisolone (15mg/day) and betamethasone 
butyrate propionate cream for 2 weeks with good clinical out-
come. But in our case: discontinuation of  sorafenib associated 
with symptomatic treatement allowed good clinical and biological 
outcome.
The pathophysiology steven johnson syndrome is like any severe 
drug reactions is unknown, but the most plausible theory is the 
assumption that a reactive metabolite is responsible [8].
 According to this theory, severe drug reactions result from expo-
sure to an increased amount of  reactive metabolites (oxidative), a 
reduced production of  nontoxic metabolites normal soluble and 
/ or a reduced ability to detoxify reactive metabolites. But the 
sorafenib molecular mechanism of  this type of  toxicity remains 
unknown and further studies will be required to elucidate it as well 
Figure 1. Skin eruptions seen on the back of  a patient who showed SJS
Figure 2. Cheilitis induced by sorafenib
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as identify an effective treatment strategy [8].
 
Whatever the pathophysiological mechanism, sorafenib cannot be 
readministered to a patient who has had this toxic skin reaction.
Conclusion
The new targeted therapies have been commonly used in patients 
with metastatic carcinoma.
Patients treated with sorafenib for HCC should be monitored 
closely with a multidisciplinary approach, and if  SJS is diagnosed, 
these patients cannot be given sorafenib again.
We recommended dermatologic examination of  patients who 
have cutaneous eruptions while receiving multikinase inhibitors, 
and, if  necessary, skin biopsy must be performed for distinguish-
ing the cutaneous side effects of  these agents. We must be very 
careful and follow up these patients with a multidisciplinary ap-
proach. 
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